NZ591525A - Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin - Google Patents

Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin

Info

Publication number
NZ591525A
NZ591525A NZ591525A NZ59152509A NZ591525A NZ 591525 A NZ591525 A NZ 591525A NZ 591525 A NZ591525 A NZ 591525A NZ 59152509 A NZ59152509 A NZ 59152509A NZ 591525 A NZ591525 A NZ 591525A
Authority
NZ
New Zealand
Prior art keywords
skin
oritavancin
treatment
methods
complicated
Prior art date
Application number
NZ591525A
Other languages
English (en)
Inventor
Thomas R Parr
Dario Lehoux
Gregory Moeck
Pierre Etienne
Original Assignee
Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591525(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicines Co filed Critical Medicines Co
Publication of NZ591525A publication Critical patent/NZ591525A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NZ591525A 2008-08-30 2009-08-29 Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin NZ591525A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9331408P 2008-08-30 2008-08-30
US9349708P 2008-09-02 2008-09-02
PCT/US2009/055466 WO2010025438A2 (en) 2008-08-30 2009-08-29 Methods of treatment using single doses of oritavancin

Publications (1)

Publication Number Publication Date
NZ591525A true NZ591525A (en) 2014-03-28

Family

ID=41722337

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591525A NZ591525A (en) 2008-08-30 2009-08-29 Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin

Country Status (18)

Country Link
US (2) US8420592B2 (enExample)
EP (3) EP3006038B1 (enExample)
JP (1) JP5782615B2 (enExample)
CN (2) CN102215858A (enExample)
AU (1) AU2009285564B2 (enExample)
CA (1) CA2736860C (enExample)
DK (2) DK2337575T3 (enExample)
EA (1) EA020490B1 (enExample)
ES (2) ES2570401T3 (enExample)
FI (1) FI3006038T3 (enExample)
HU (3) HUE027373T2 (enExample)
MX (1) MX2011002249A (enExample)
NL (1) NL300834I2 (enExample)
NO (1) NO2016019I2 (enExample)
NZ (1) NZ591525A (enExample)
PL (2) PL2337575T3 (enExample)
PT (1) PT3006038T (enExample)
WO (1) WO2010025438A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027373T2 (hu) * 2008-08-30 2016-09-28 The Medicines Co Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával
PT2424559T (pt) 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
WO2014031681A1 (en) * 2012-08-20 2014-02-27 The University Of Chicago Inhibiting gram positive bacteria
US20160101148A1 (en) * 2013-04-22 2016-04-14 The Medicines Company Treatment and prevention of bacterial skin infections using oritavancin
US20160206688A1 (en) * 2013-08-26 2016-07-21 The Medicines Company Methods for treating bacteremia and osteomyelitis using oritavancin
WO2015031579A2 (en) * 2013-08-28 2015-03-05 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins
WO2015192031A1 (en) * 2014-06-12 2015-12-17 Cem-102 Pharmaceuticals, Inc. Compositions and methods for treating bone and joint infections
CN107206050A (zh) * 2014-07-17 2017-09-26 医药公司 高纯度奥利万星及其生产方法
KR20180111948A (ko) * 2016-02-18 2018-10-11 멜린타 테라퓨틱스, 인크. 오리타반신 제제
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
CN108409837B (zh) * 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5994297A (en) * 1997-08-22 1999-11-30 Eli Lilly And Company Therapy for Staphylococcus aureus
DE60016734T2 (de) * 1999-05-03 2005-12-08 Eli Lilly And Co., Indianapolis Monatliche gaben von glykopeptid-antibiotika zur langzeitprävention von streptokokkus pneumoniae infektionen
ES2316445T3 (es) 2000-05-02 2009-04-16 Theravance, Inc. Composicion que contiene una ciclodextrina y un antibiotico glicopeptidico.
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
CN1662643A (zh) * 2002-05-28 2005-08-31 贝克顿·迪金森公司 人腺泡细胞的扩增和转分化
AU2003274927A1 (en) * 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
US9089507B2 (en) * 2006-09-25 2015-07-28 The Medicines Company Use of oritavancin for prevention and treatment of anthrax
HUE027373T2 (hu) * 2008-08-30 2016-09-28 The Medicines Co Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával
PT2424559T (pt) * 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
WO2015031579A2 (en) * 2013-08-28 2015-03-05 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins

Also Published As

Publication number Publication date
EA020490B1 (ru) 2014-11-28
NL300834I2 (enExample) 2016-11-16
EP2337575B1 (en) 2016-04-13
MX2011002249A (es) 2011-06-24
AU2009285564B2 (en) 2014-05-22
HUE027373T2 (hu) 2016-09-28
US8420592B2 (en) 2013-04-16
PL3006038T3 (pl) 2024-11-12
US20130172237A1 (en) 2013-07-04
CN106620649A (zh) 2017-05-10
US20110201546A1 (en) 2011-08-18
WO2010025438A9 (en) 2010-05-14
DK3006038T3 (da) 2024-08-26
JP2012501349A (ja) 2012-01-19
CA2736860A1 (en) 2010-03-04
DK2337575T3 (en) 2016-05-23
CA2736860C (en) 2020-04-28
WO2010025438A2 (en) 2010-03-04
EP3006038B1 (en) 2024-07-03
EA201100413A1 (ru) 2012-01-30
AU2009285564A1 (en) 2010-03-04
CN102215858A (zh) 2011-10-12
ES2994966T3 (en) 2025-02-04
EP2337575A4 (en) 2012-10-17
EP3006038A1 (en) 2016-04-13
EP2337575A1 (en) 2011-06-29
FI3006038T3 (fi) 2024-08-12
HUS1600039I1 (hu) 2016-11-28
EP4464375A2 (en) 2024-11-20
NO2016019I2 (no) 2019-01-25
PL2337575T3 (pl) 2016-09-30
ES2570401T3 (es) 2016-05-18
JP5782615B2 (ja) 2015-09-24
EP4464375A3 (en) 2025-02-26
NO2016019I1 (no) 2016-10-11
HUE068423T2 (hu) 2024-12-28
PT3006038T (pt) 2024-08-23

Similar Documents

Publication Publication Date Title
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
JP2013155188A5 (enExample)
FI3494972T3 (fi) Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon
NZ597378A (en) Treatment of multiple sclerosis with laquinimod
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
NZ595767A (en) Composition for the treatment of prostate cancer
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2008022189A3 (en) Administration of high potency platinum compound formulations by inhalation
NZ714963A (en) Compositions and methods for treating anemia
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
PH12013500559A1 (en) Combination therapy for treating hcv infection
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
GB2456475A (en) Composition for the treatment of skin conditions
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
MX2019002894A (es) Combinaciones con un peptido ciclado con la estructura de la base.
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
MXPA02009603A (es) Terapias de dosis divididas con actividad de deterioro vascular.
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
WO2007144889A3 (en) Treatment of neurofibromatosis
RU2012114097A (ru) Терапевтический агент против хронической боли

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN; FILING DATE: 04 MAR 2011; STATUS: REJECTED; TITLE: METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN; FILING DATE: 03 OCT 2012; STATUS: REJECTED; TITLE: METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN; FILING DATE: 20 JUL 2011; STATUS: REJECTED; TITLE: METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN; FILING DATE: 20 JUL 2011; STATUS: REJECTED; TITLE: METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN; FILING DATE: 18 MAR 2013; STATUS: PROPOSED;

Effective date: 20130403

ASS Change of ownership

Owner name: THE MEDICINES COMPANY, US

Effective date: 20140213

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 AUG 2016 BY DAVIES COLLISON CAVE

Effective date: 20140702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2017 BY THOMSON REUTERS

Effective date: 20160714

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2018 BY THOMSON REUTERS

Effective date: 20170720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2019 BY THOMSON REUTERS

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2020 BY THOMSON REUTERS

Effective date: 20190725

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2021 BY THOMSON REUTERS

Effective date: 20200721

ASS Change of ownership

Owner name: MELINTA THERAPEUTICS, INC., US

Effective date: 20200820

LECA Licensee/mortgages/financial interest

Name of requester: A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.

Effective date: 20201020

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2022 BY THOMSON REUTERS

Effective date: 20210702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2023 BY THOMSON REUTERS

Effective date: 20220704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2024 BY THOMSON REUTERS

Effective date: 20230703

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2025 BY THOMSON REUTERS

Effective date: 20240702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 AUG 2026 BY THOMSON REUTERS

Effective date: 20250701